Roche said it will start a Phase 2 trial combining two obesity and metabolic candidates—petrelintide and enicepatide—during 2026. The company framed the approach as a way to test whether the combination can improve safety and efficacy beyond Roche’s individual obesity programs. The pairing matters for a crowded obesity market because dosing, tolerability, and cardiovascular safety remain central decision points for payers and regulators. Roche positioned the programs as having best-in-class potential individually, while testing synergy as it prepares for the next phase of development. As clinical-stage obesity candidates proliferate, combination studies like Roche’s can help differentiate pipelines by addressing both weight-loss depth and maintenance while monitoring signal quality across organ systems.